Interim results from phase IIa trial evaluating triple

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 9, 2016 at 6:45 AM

Interim results from phase IIa trial evaluating triple combination including simeprevir demonstrates high level of efficacy in HCV patients

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that interim results from a phase IIa study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen), were published as part of the abstracts released for the upcoming European Association for the Study of the Liver (EASL) Special Conference, September 23-24, 2016, in Paris, France. Interim results from cohorts 1-4, summarized in the table below, showed that the triple combination regimen, including simeprevir, was highly effective and well tolerated in non-cirrhotic patients with GT1 HCV. Additional results, including sustained viral response 12 weeks after completion of therapy (SVR12) for all cohorts, will be presented in the eposter presentation on Friday, September 23, 2016. +------+----------+----------+------+---------+------------------------------+ |Cohort|Simeprevir|Odalasvir |AL-335|Treatment|Number (%) with undetectable* | |# |dose (mg) |dose (mg) | dose |Duration |HCV RNA at EOT or SVR12 or 24 | | | | |(mg) | (weeks) | | +------+----------+----------+------+---------+------------------------------+ |1 | 100 QD | 50 QD |400 QD| 8 | 20/20 (100%), SVR24 | +------+----------+----------+------+---------+------------------------------+ |2 | -- | 50 QOD |800 QD| 8 | 18/20 (90%), SVR12 | +------+----------+----------+------+---------+------------------------------+ |3 | 75 QD | 50 QOD |800 QD| 8 | 20/20 (100%), SVR4 | +------+----------+----------+------+---------+------------------------------+ |4 | 75 QD | 50 QOD |800 QD| 6 | 20/20 (100%), EOT | +------+----------+----------+------+---------+------------------------------+ *Or below the limit of quantification (N=2; Cohort 4 only) EOT: end of treatment; QD: every day; QOD: every other day; RNA: ribonucleic acid; SVR: sustained virologic response. Of the 20 patients treated in cohort 1, who received the triple combination of odalasvir (50mg QD), AL-335 (400mg QD) and simeprevir (100mg QD) for eight weeks (triplet, 8 weeks), 100 percent remained HCV RNA undetectable 24 weeks after completing therapy (SVR24). Additional patients were subsequently enrolled into two further cohorts (3 & 4), where they received adjusted doses of the same triple combination for either eight or six weeks. In cohort 3 all patients were HCV RNA negative (N=18) or below the limit of quantitation (N=2) and remained HCV RNA undetectable 4 weeks after completing therapy (SVR4) and in cohort 4 all patients were HCV RNA negative at end of treatment. Of the 20 patients treated in cohort 2, who received the dual combination of odalasvir (50mg QOD) and AL -335 (800mg QD) for eight weeks (8 weeks), 90 percent remained HCV RNA undetectable twelve weeks after completing therapy (SVR12). These all-oral combination regimens containing odalasvir and AL-335, with or without simeprevir, were generally safe and well tolerated. The majority of adverse events (AEs) were mild, most commonly headache, fatigue, and upper respiratory tract infection. No clinically significant laboratory abnormalities were observed. In cohort 1, there was a single serious adverse event (Mobitz Type 1 2nd degree atrioventricular block), which was attributed to treatment. This ECG abnormality was not associated with clinical or echocardiographic abnormalities, was transient and resolved following treatment discontinuation, and the patient went on to achieve SVR24. Further Development of the Triple Combination Based upon the interim data from the phase IIa study, a phase II program is in place for the development of the triple combination of simeprevir, odalasvir and AL-335. This program will include two multi-center, randomized, open-label studies that will enroll treatment-naive and treatment-experienced non-cirrhotic patients chronically infected with hepatitis C virus genotypes 1, 2, 4, 5, and 6. These two studies will be complemented by an expansion of the ongoing phase IIa study, to allow the triple combination to be studied in additional patients with or without compensated cirrhosis, and with HCV genotype 2 and 3 infection. For further information, please contact: Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580 Richard Bethell, CSO Medivir AB, mobile +46 (0)72 704 3211 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 12.30 CET on 9thof September 2016. About Medivir Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Hit and Run Protocols in St. Tammany Parish

When the Driver Disappears: Steps Forward Hit and run accidents can leave you feeling abandoned and unsure of what to do. In St. Tammany Parish, this scenario is all too familiar. Personal Injury Attorney Ross F. Lagarde cuts through the chaos, offering a clear path for those caught in this nightmare, explained in HelloNation's comprehensive guide. Prioritize Safety and...

Stravito's MCP Server Revolutionizes AI in Business

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...

Kansas City Current's Grand Playoff Push in 2026

A Celebration of Fans and Momentum Some things are bigger than just a match. The Kansas City Current’s event, 'One Current 2026: Bigger Home. Bigger Future.' ain't just another day on the pitch. This is about expanding a vision that has the whole town buzzing. On Sunday, October 25, the buzzhits fever pitch as CPKC Stadium rolls out the biggest event in its...

Infrared Imaging Expands with AI, SWIR: Tech Trends

Infrared Imaging: The Backbone of Future Tech Kinda wild how infrared imaging's become a hot topic in tech circles. With the market expected to jump from USD 9.2 billion in 2026 to a hefty USD 12.6 billion by 2031, averaging a 6.4% growth rate, there's plenty to chew on. Even if you ain't the analytical type, it ain't hard to spot where the money's flowing. Infrared's...

Decision Logic Innovates with Vitals & ShiftFlow Tools

Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...

1.8M Moves in England: The Admin Maze Explained

Navigating the Address Change Labyrinth Every time that welcome mat rolls out in a new spot, you're signing up for a mountain of paperwork. Sloth Move just painted a picture of the administrative mess awaiting those 1.8 million English households that decided 'new view, new digs' last year. Their analysis highlights why moving home means more than packing boxes—it's...

Wrensilva Unveils Studio Console in White Oak

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

PostalAnnex Lands at Stanford with New Service Hub

PostalAnnex Makes a Strategic Stanford Move It's not every day you see a company nestling into a place like Stanford University. Annex Brands has just opened its latest PostalAnnex location, a stone’s throw from the academic hustle and bustle of the Stanford campus. The geeky vibe of students and professors rushing with deadlines matches well with the efficient service...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Synopsys-TSMC Collaboration Drives AI System Evolution

Synopsys and TSMC: The New Power Couple in AI Ah, the world of semiconductors—where the chips are small but the stakes are colossal. Once again, Synopsys and TSMC have thrown their hats into the ring, diving headfirst into yet another ambitious collaboration. Their latest mission? To fast-track the evolution of AI systems through a suite of innovations strapped to...